Serum Irisin and its Relation to Insulin Resistance in Patients with Psoriasis

Abstract

Abstract Background Psoriasis is a chronic inflammatory disease that affects the skin and joints. Psoriasis affects about 2-3% of the world population. The pathogenesis of psoriasis involves dynamic interactions between multiple cell types and numerous cytokines in response to triggers leading to disruption of skin immune homeostasis in genetically predisposed individuals. Aim of the Work This study done aimed to evaluate serum irisin level in psoriatic patients and elucidate possible associations with insulin resistance and disease activity. Patients and Methods This comparative case control study included thirty five psoriatic patients with generalized plaque psoriasis and thirty five non psoriatic, sex and age matched persons who served as a control group. The patients were selected from patients attending the Outpatient Clinic of Dermatology, venerology and Andrology Department of Ain Shams University Hospitals, from March 2022 to July 2022. Results We measured serum level of irisin, fasting insulin and glucose level then calculated HOMA IR. Our results showed statistically significant increase in fasting insulin levels, FBG levels and HOMA IR between Psoriasis patients and controls. Also, median serum irisin level was higher in psoriatic patients compared with controls and there was statistically positive correlation found between serum levels of irisin and severity of psoriasis (PASI). Yet, no significant correlation found between serum irisin levels and HOMA-IR among studied subjects. Conclusion Serum irisin levels were insignificantly increased in patients with psoriasis reflecting its possible role in pathogenesis of psoriasis. Moreover, it was positively correlated with severity of disease. Thus, can be possibly used as an indicator of disease severity.